Skip to main content
SpringerLink
Log in

In Vitro Protection from Cisplatin-induced Neurotoxicity by Amifostine and its Metabolite WR1065

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Cisplatin-induced neuropathy is a major dose-limiting toxicity. Counteraction by amifostine and its metabolite WR1065 may reduce peripheral neurotoxicity in a number of patients. Using the nerve growth factor (NGF)-dependent neurite outgrowth from the PC12 pheochromocytoma cell line as an in vitro assay for neurotoxicity, the protective effects of amifostine and WR1065 against cisplatin action on neurite formation by PC12 cells were studied.

Cisplatin in a concentration of 10 µg/ml significantly decreased the percentage of neurite forming cells from 84% to 40%. Amifostine in doses of 0.4 and 0.8 mM proved to protect significantly against the cisplatin-induced decrease in neurite formation, when co-incubated with cisplatin. Also the metabolite WR1065 protected significantly against cisplatin neurotoxicity in a dose of 0.12 mM. Our results show a significant protection by amifostine and its main metabolite WR1065 against cisplatin-induced neurotoxicity using an in vitro model.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Roelofs RI, HrusheskyW, Rogin J, Rosenberg L: Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34: 934–938, 1984

    PubMed  Google Scholar 

  2. Gerritsen van der Hoop RG, van der Burg MEL, ten Bokkel Huinink WW, van Houwelingen C, Neijt JP: Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 66: 1697–1702, 1990

    PubMed  Google Scholar 

  3. Riggs JE, Ashraf M, Snyder RD, Gutmann L: Prospective nerve conduction studies in cisplatin therapy. Ann Neurol 23: 92–94, 1988

    PubMed  Google Scholar 

  4. Walsh TJ, Clark AW, Pahrad IM, Green WR: Neurotoxic effects of cisplatin therapy. Arch Neurol 39: 719–720, 1982

    PubMed  Google Scholar 

  5. Daugaard GK, Petrera J, Trojaborg W: Electrophysiological study of the peripheral and central neurotoxic effects of cisplatin. Acta Neurol Scand 76: 86–93, 1987

    PubMed  Google Scholar 

  6. Gregg RW, Molepo JM, Monpetit VJA, Mikael NZ, Redmond D, Gadia M, Stewart DJ: Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10: 795–803, 1992

    PubMed  Google Scholar 

  7. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J: Amifostine pretreatment for protection against cyclophosphamide-induced and 5 cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14: 2101–2112, 1996

    PubMed  Google Scholar 

  8. Spencer CM, Goa KL: Amifostine, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector (Review). Drugs 50: 1001–1031, 1995

    PubMed  Google Scholar 

  9. Treskes M, Nijtmans L, Fichtinger Schepman AM, van der Vijgh WJF: Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts. Anticancer Res 12: 2261–2266, 1992

    PubMed  Google Scholar 

  10. Nakamura J, Shaw LM, Brown DQ: Hydrolysis of WR2721 by mouse liver cell fractions. Radiat Res 109: 143–152, 1987

    PubMed  Google Scholar 

  11. Yuhas JM, Spellman JM, Jordan SW, Pardini MC, Afzal SMJ, Culo F: Treatment of tumours with the combination of WR2721 and cis-diamminedichloroplatinum-(II) or cyclophosphamide. Br J Cancer 42: 547–585, 1980

    Google Scholar 

  12. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC: Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197: 165–167, 1977

    PubMed  Google Scholar 

  13. Treskes M, Nijtmans LG, Fichtinger Schepman AMJ, van der Vijgh WJ: Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol 43: 1013–1019, 1992

    PubMed  Google Scholar 

  14. DeNeve WJ, Everett CK, Suminski JE, Valeriote FA: Influence of WR2721 onDNAcross-linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo. Cancer Res 48: 6002–6005, 1988

    PubMed  Google Scholar 

  15. Geldof AA: Nerve-growth-factor-dependent neurite outgrowth assay; a research model for chemotherapy-induced neuropathy. J Cancer Res Clin Oncol 121: 657–660, 1995

    PubMed  Google Scholar 

  16. Geldof AA, Minneboo A, Heimans JJ: Vinca-alkaloid neurotoxicity measured using an in vitro model. J Neurooncol 37: 109–113, 1998

    PubMed  Google Scholar 

  17. Brown DW, Graham WJ, McKenzie LJ, Pittock JW, Shaw LM: Can WR2721 be improved upon? Pharmacol Ther 39: 157–168, 1988

    PubMed  Google Scholar 

  18. Greene LA, Tischler AS: Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which responds to nerve growth factor. Proc Natl Acad Sci USA 73: 2424–2428, 1976

    PubMed  Google Scholar 

  19. Shpall EJ, Stemmer SM, Hami L, Franklin WA, Shaw L, Bonner HS, Bearman SI, Peters WP et al.: Amifostine (WR2721) shortens the engraftment period of 4–hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 83: 3132–3137, 1994

    PubMed  Google Scholar 

  20. Douay L, Hu C, Giarratana MC, Bouchet S, Conlon J, Capizzi RI, Gorin NC: Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood 86: 2849–2855, 1995

    PubMed  Google Scholar 

  21. Meier T, Issels RD: Degradation of 2–(3–aminopropylamino)-ethanethiol (WR1065) by Cu-dependent amine oxidases and influence on glutathione status of Chinese hamster ovary cells. Biochem Pharmacol 50: 489–496, 1995

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands

    C.C.P. Verstappen, T.J. Postma & J.J Heimans

  2. Departments of Endocrinology/Nucl. Medicine and Urology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands

    A.A. Geldof

Authors
  1. C.C.P. Verstappen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A.A. Geldof
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T.J. Postma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J.J Heimans
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Verstappen, C., Geldof, A., Postma, T. et al. In Vitro Protection from Cisplatin-induced Neurotoxicity by Amifostine and its Metabolite WR1065. J Neurooncol 44, 1–5 (1999). https://doi.org/10.1023/A:1006241622639

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006241622639

Search

Navigation